Nonalcoholic Steatohepatitis (NASH)

1 min read
Nonalcoholic Steatohepatitis (NASH) Blog Image


Madrigal Pharmaceuticals Inc.’s drug Rezdiffra gained the first US approval to treat a potentially deadly liver disease called nonalcoholic steatohepatitis, or NASH that affects millions worldwide.

About Nonalcoholic Steatohepatitis (NASH)

  • It is liver inflammation and damage caused by a buildup of fat in the liver.
  • It is part of a group of conditions called nonalcoholic fatty liver disease.
  • NASH can get worse and cause scarring of the liver, which leads to cirrhosis. But the disease doesn't always get worse.
  • It is similar to the kind of liver disease that is caused by long-term, heavy drinking. But NASH occurs in people who don't abuse alcohol.
  • Symptoms: As NASH progresses and liver damage gets worse, you may start to have symptoms such as:
    • Fatigue (feeling tired all the time).
    • Weight loss for no clear reason.
    • General weakness.
    • An ache in the upper right part of your belly.
  • Causes: Things that put people at risk for NASH and for liver damage include: obesity, Insulin resistance and type 2 diabetes, high cholesterol and high triglycerides, metabolic syndrome etc.
  • Treatment for NASH includes managing conditions that increase your risk for NASH or make it worse. You can:
    • Reduce your total cholesterol level.
    • Reach a healthy weight. Losing 3% to 10% of your total body weight can make a difference.
    • Control diabetes.

Q1) What is the function of liver?

The liver is a critical organ in the human body that is responsible for an array of functions that help support metabolism, immunity, digestion, detoxification, vitamin storage among other functions.

Source: First drug to treat common, lethal liver disease gets US nod